CRS3123 for C. difficile
Keystone Symposia: Antimicrobial Resistance & Microbiome Presentation
Keystone Symposia Presentation Details Poster: Phase 2 Clinical Trial Design for CRS3123, a Novel...
Read More
Presentation: World Antimicrobial Resistance (WAMR) Conference 2022
WAMR Conference 2022 Presentation Details Poster Presentation: Addressing the AMR Challenge:...
Read More
C. diff Infection Symptoms: An Overview
Clostridium difficile infection (CDI) is a gastrointestinal condition caused by toxin-producing...
Read More
Presentation at the 2022 National C. Diff Advocacy Summit
2022 National C. Diff Advocacy Summit Presentation Details Crestone presents at the largest...
Read More
Presentation at the C. diff International Conference & Health EXPO
C. diff International Conference & Health EXPO Presentation Details Crestone, Inc. presents at...
Read More
Crestone, Inc. joins the Antimicrobials Working Group
June 8, 2021 – Announcement: Crestone, Inc. joins the Antimicrobials Working Group to Combat...
Read More
First Patient Enrolled in Phase 2 Clinical Trial + QIDP & Fast Track
June 7, 2021 – Announcement: Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial...
Read More
NIH Funding Secured for Preclinical Development of CRS3123
Apr 27, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Preclinical Development...
Read More
NIH Funding Secured for Phase 2 Clinical Trial of CRS3123
Sep 12, 2019 – Announcement: Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial...
Read More
Become a Part of Our Projects
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor, a team member, or a participant in our ongoing clinical studies.
Inquiries
Have a question or comment? Follow the link below to contact us about general inquiries.
Careers
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Clinical Studies
Learn how you can become part of our ongoing clinical study to fight deadly GI tract infections.